GLP-1 medication adoption shifts consumer dietary preferences in Brazil

Increased utilization of GLP-1 agonists like Ozempic and Wegovy is driving a shift in Brazilian consumer behavior toward high-protein, fiber-rich, and natural food products. This trend correlates with a reduction in overall caloric intake and a decline in demand for highly processed, sugar-heavy goods. The long-term impact on the domestic food retail sector remains uncertain as the market adjusts to these changing consumption patterns.